Safety and Tolerability of HTI-1066 in Subjects With Advanced Solid Tumors
Status:
Unknown status
Trial end date:
2019-12-31
Target enrollment:
Participant gender:
Summary
HTI-1066 is a novel ADC being developed for the treatment of cancers in patients with
overexpression of c-Met. This 2-part, Phase 1 study evaluates the safety the tolerability of
HTI-1066 in subjects with advanced solid tumors.